COPCOV Investigators

A global network of scientific, medical and research trial collaborators works together on COPCOV, the MORU-led, Oxford-supported study to test if hydroxychloroquine or chloroquine can prevent COVID-19.

As vaccines begin to roll out, finding drugs that prevent COVID-19 is more important than ever: It may be mid-2022 before there are enough COVID-19 vaccines for the 7.5 billion people on this planet. Scientifically proving that hydroxychloroquine provides even a small health benefit could save thousands of lives before vaccines become widely available, and COVID-19 brought under control. Understanding whether these drugs can effectively prevent COVID-19 infection would also support global preparedness for future potential emerging viral threats.

Currently, there are active COPCOV sites in the UK and Pakistan, with new sites opening soon in Indonesia, Nepal, Zambia and in other African countries. In addition, sites in Thailand and Lao PDR are set up, ready to be re-activated should COVID-19 re-emerge there.

Principal Investigators

Nicholas White

Professor of Tropical Medicine

William Schilling

Research Physician

Investigators

Nicholas Day

Professor of Tropical Medicine
Bob Taylor

Senior Clinical Research Fellow
Elizabeth Ashley

Professor of Tropical Medicine
Paul Turner

Associate Professor

Arjun Chandna

Research Physician
Guy Thwaites

Professor of Infectious Diseases
Martin Llewelyn

Professor in Infectious Diseases
Amanda Adler

Director, Diabetes Trials Unit

Phaik Yeong Cheah

Associate Professor
Adrianus Dondorp

Professor of Tropical Medicine
Mayfong Mayxay

Vice-President of the Lao University of Health Sciences, Ministry of Health
James Callery

Research Physician